Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 95 points (0.6%) at 16,678 as of Monday, May 12, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,394 issues advancing vs. 601 declining with 132 unchanged. The Drugs industry currently sits up 1.7% versus the S&P 500, which is up 0.8%. Top gainers within the industry include Regeneron Pharmaceuticals ( REGN), up 3.9%, Alexion Pharmaceuticals ( ALXN), up 3.4%, Vertex Pharmaceuticals ( VRTX), up 2.6%, Grifols ( GRFS), up 2.4% and Mylan ( MYL), up 2.4%. A company within the industry that fell today was Shire ( SHPG), up 0.8%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Bristol-Myers Squibb Company ( BMY) is one of the companies pushing the Drugs industry higher today. As of noon trading, Bristol-Myers Squibb Company is up $0.88 (1.7%) to $52.06 on average volume. Thus far, 4.7 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 8.5 million shares. The stock has ranged in price between $51.35-$52.31 after having opened the day at $51.52 as compared to the previous trading day's close of $51.18. Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company has a market cap of $84.1 billion and is part of the health care sector. Shares are down 3.7% year-to-date as of the close of trading on Friday. Currently there are 11 analysts who rate Bristol-Myers Squibb Company a buy, 2 analysts rate it a sell, and 5 rate it a hold. TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, good cash flow from operations, solid stock price performance and notable return on equity. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Bristol-Myers Squibb Company Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.